奥浦迈: 奥浦迈：关于本次发行股份及支付现金购买资产并募集配套资金事项的风险提示性公告

Group 1 - The company plans to acquire 100% equity of Pengli Bio by issuing shares and paying cash, while also raising supporting funds from no more than 35 specific investors [1][2] - The stock of the company will be suspended from trading starting January 17, 2025, due to the uncertainties surrounding the transaction, and will continue to be suspended until January 24, 2025 [2][3] - The board of directors has approved the proposal for the acquisition and fundraising, with relevant documents published on the Shanghai Stock Exchange website [3] Group 2 - The transaction is subject to several conditions, including approval from the shareholders' meeting, review by the Shanghai Stock Exchange, and consent from the China Securities Regulatory Commission [4]